CD19 and lymphoma: Immunohistochemical analysis of spleens showed a marked reduction of CD19+ lymphoma cell infiltration with concomitant increase of CD68+ macrophage infiltration after treatment with alemtuzumab and S3 in comparison to vehicle control (Figures 7G and S7C).